Phase 2 (162 companies)
Companies with at least one active program at Phase 2.
| Ticker | Company | Therapeutic areas | Phase 2 programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| FDMT | 4D Molecular Therapeutics | OphthalmologyRespiratory Rare | 1 | Phase 3 | $608M | 5 |
| ABVX | Abivax | Immunology | 1 | Phase 3 | $7.19B | 2 |
| ACIU | AC Immune | Neurology Rare | 4 | Phase 3 | $210M | 11 |
| QUIT | Achieve Life Sciences | — | 1 | NDA Submitted | $673M | 2 |
| ACRS | Aclaris Therapeutics | DermatologyGI/Hepatology+1 Rare | 2 | Phase 2 | $536M | 7 |
| ACRV | Acrivon Therapeutics | GI/HepatologyOncology Rare | 4 | Phase 2 | $61.4M | 9 |
| ACTU | Actuate Therapeutics | Oncology | 1 | Phase 2 | $15.2M | 4 |
| ABOS | Acumen Pharmaceuticals | Neurology | 1 | Phase 2 | $16.6M | 4 |
| ADAG | Adagene | Oncology | 3 | Phase 2 | $99.4M | 10 |
| ADCT | ADC Therapeutics | Oncology | 3 | Approved | $172M | 5 |
| AGIO | Agios Pharmaceuticals | HematologyMetabolic Rare | 1 | Approved | $1.79B | 7 |
| AGMB | Agomab Therapeutics | ImmunologyRespiratory Rare | 1 | Phase 2 | $292M | 4 |
| AKBA | Akebia Therapeutics | HematologyOphthalmology+2 Rare | 4 | Approved | $111M | 10 |
| ALLO | Allogene Therapeutics | ImmunologyOncology Rare | 1 | Phase 2 | $256M | 10 |
| DRTS | Alpha Tau Medical | Oncology | 4 | Phase 2 | $1.12B | 6 |
| ATHE | Alterity Therapeutics | Neurology Rare | 1 | Phase 2 | $35.7M | 2 |
| ALT | Altimmune | GI/HepatologyMetabolic+1 | 2 | Phase 3 | $298M | 3 |
| ANRO | Alto Neuroscience | Neurology | 6 | Phase 2 | $999M | 6 |
| ALMS | Alumis | DermatologyImmunology+1 | 1 | Phase 3 | $628M | 5 |
| AMLX | Amylyx Pharmaceuticals | MetabolicNeurology Rare | 1 | Phase 3 | $3.54B | 5 |
| ANTX | AN2 Therapeutics | HematologyInfectious Disease+1 Rare | 1 | Phase 2 | $161M | 6 |
| ANAB | AnaptysBio | DermatologyGI/Hepatology+2 Rare | 1 | Approved | $1.36B | 9 |
| ANNX | Annexon | HematologyNeurology+2 Rare | 2 | Phase 3 | $662M | 6 |
| APGE | Apogee Therapeutics | DermatologyGI/Hepatology+1 Rare | 1 | Phase 2 | — | 9 |
| ARVN | Arvinas | NeurologyOncology Rare | 1 | Approved | $447M | 10 |
| ATAI | Atai Beckley | Neurology | 3 | Phase 2 | $2.73B | 5 |
| AUTL | Autolus Therapeutics | HematologyImmunology+3 Rare | 2 | Approved | $290M | 12 |
| AXSM | Axsome Therapeutics | Neurology Rare | 1 | Approved | $7.15B | 15 |
| BEAM | Beam Therapeutics | HematologyMetabolic+1 Rare | 1 | Phase 2 | $2.14B | 6 |
| BCAX | Bicara Therapeutics | Oncology | 1 | Phase 2 | $637M | 4 |
| BCYC | Bicycle Therapeutics | Oncology | 2 | Phase 2 | $224M | 4 |
| BIOA | BioAge Labs | CardiovascularOphthalmology | 2 | Phase 2 | $234M | 2 |
| BMEA | Biomea Fusion | MetabolicOncology | 2 | Phase 2 | $35.5M | 4 |
| BDTX | Black Diamond Therapeutics | Oncology | 2 | Phase 2 | $82.8M | 4 |
| CCCC | C4 Therapeutics | Oncology | 1 | Phase 2 | $332M | 2 |
| CRDL | Cardiol Therapeutics | Cardiovascular Rare | 1 | Phase 3 | $124M | 4 |
| RNAC | Cartesian Therapeutics | ImmunologyNeurology+1 Rare | 1 | Phase 3 | $187M | 4 |
| CLDX | Celldex Therapeutics | DermatologyImmunology+1 | 1 | Phase 3 | $2.20B | 6 |
| CLRB | Cellectar Biosciences | Oncology | 4 | Phase 2 | $9.2M | 7 |
| CRVO | CervoMed | Neurology Rare | 3 | Phase 2 | $22.7M | 4 |
| CMMB | Chemomab Therapeutics | GI/HepatologyImmunology+1 Rare | 2 | Phase 2 | $13.2M | 4 |
| CLNN | Clene | Neurology Rare | 2 | NDA Submitted | $46.4M | 5 |
| CLYM | Climb Bio | HematologyImmunology+1 Rare | 2 | Phase 2 | $574M | 8 |
| CGTX | Cognition Therapeutics | Neurology | 2 | Phase 2 | $59.9M | 2 |
| CHRS | Coherus Oncology | Oncology | 1 | Approved | $74.0M | 5 |
| CMPS | COMPASS Pathways | Neurology | 2 | NDA Submitted | $1.13B | 3 |
| CMPX | Compass Therapeutics | Oncology | 2 | Phase 2 | $109M | 15 |
| CGEN | Compugen | Oncology | 1 | Phase 3 | $191M | 7 |
| CNTB | Connect Biopharma | Respiratory | 4 | Phase 2 | $37.3M | 4 |
| CTNM | Contineum Therapeutics | NeurologyRespiratory Rare | 3 | Phase 2 | $375M | 4 |
| CRVS | Corvus Pharmaceuticals | DermatologyOncology+1 Rare | 3 | Phase 3 | $858M | 7 |
| COYA | Coya Therapeutics | Neurology Rare | 1 | Phase 2 | $70.8M | 6 |
| CBIO | Crescent Biopharma | Oncology | 1 | Phase 2 | $507M | 10 |
| CRNX | Crinetics Pharmaceuticals | MetabolicOncology Rare | 1 | Approved | — | 6 |
| CUE | Cue Biopharma | ImmunologyOncology | 1 | Phase 2 | $23.7M | 6 |
| CGEM | Cullinan Therapeutics | HematologyImmunology+2 Rare | 1 | NDA Submitted | $602M | 10 |
| CYDY | CytoDyn | NeurologyOncology | 2 | Phase 2 | $367M | 3 |
| DFTX | Definium Therapeutics | Neurology | 1 | Phase 3 | $4.02B | 4 |
| IRON | Disc Medicine | GI/HepatologyHematology+2 Rare | 3 | Phase 3 | $3.49B | 9 |
| EWTX | Edgewise Therapeutics | Cardiovascular | 3 | Phase 2 | $4.60B | 3 |
| EIKN | Eikon Therapeutics | Oncology | 2 | Phase 2 | $279M | 13 |
| ELDN | Eledon Pharmaceuticals | ImmunologyMetabolic+1 Rare | 2 | Phase 2 | $167M | 3 |
| ELTX | Elicio Therapeutics | Oncology | 1 | Phase 2 | $40.5M | 6 |
| ELOX | Eloxx Pharmaceuticals | DermatologyRenal Rare | 1 | Phase 2 | $48.0M | 4 |
| ENTA | Enanta Pharmaceuticals | DermatologyImmunology+2 | 3 | Approved | $253M | 8 |
| ENTX | Entera Bio | GI/HepatologyMetabolic Rare | 2 | Phase 2 | $522M | 4 |
| ETON | Eton Pharmaceuticals | GI/HepatologyInfectious Disease+3 Rare | 1 | Approved | $1.84B | 17 |
| EVMN | Evommune | DermatologyImmunology+1 | 3 | Phase 2 | $290M | 6 |
| EXEL | Exelixis | CardiovascularOncology | 3 | Approved | $16.7B | 23 |
| FATE | Fate Therapeutics | ImmunologyOncology+1 Rare | 1 | Phase 2 | $124M | 10 |
| FBRX | Forte Biosciences | DermatologyGI/Hepatology | 1 | Phase 2 | — | 3 |
| FBIO | Fortress Biotech | DermatologyHematology+4 Rare | 2 | Approved | $61.4M | 16 |
| GNLX | Genelux | Oncology | 1 | Phase 3 | $96.1M | 3 |
| GERN | Geron | Oncology | 1 | Approved | $644M | 3 |
| GHRS | GH Research | NeurologyWomen's Health | 3 | Phase 2 | $1.25B | 4 |
| GOSS | Gossamer Bio | Cardiovascular Rare | 2 | NDA Submitted | $67.5M | 4 |
| HRMY | Harmony Biosciences | MetabolicNeurology Rare | 1 | Approved | $1.94B | 17 |
| HROW | Harrow | Ophthalmology Rare | 1 | Approved | $1.11B | 15 |
| HELP | Helus Pharma | Neurology | 2 | Phase 3 | $575M | 3 |
| IMUX | Immunic | GI/HepatologyNeurology | 1 | Phase 3 | $116M | 4 |
| IBRX | ImmunityBio | Infectious DiseaseOncology | 7 | Approved | $6.66B | 17 |
| IMVT | Immunovant | ImmunologyNeurology Rare | 3 | Phase 3 | $6.87B | 4 |
| IXHL | Incannex Healthcare | NeurologyRespiratory | 2 | Phase 2 | $21.8M | 2 |
| INBX | Inhibrx Biosciences | Oncology | 1 | NDA Submitted | $1.10B | 6 |
| IONS | Ionis Pharmaceuticals | CardiovascularHematology+5 Rare | 1 | Approved | $4.49B | 29 |
| JBIO | Jade Biosciences | ImmunologyRenal Rare | 1 | Phase 2 | $1.07B | 4 |
| KAPA | Kairos Pharma | Oncology | 1 | Phase 2 | $1.9M | 12 |
| KZIA | Kazia Therapeutics | NeurologyOncology Rare | 6 | Phase 2 | $60.7M | 13 |
| KROS | Keros Therapeutics | NeurologyOncology Rare | 1 | Phase 3 | $222M | 5 |
| KPRX | Kiora Pharmaceuticals | Ophthalmology Rare | 2 | Phase 3 | $4.1M | 4 |
| KYMR | Kymera Therapeutics | DermatologyImmunology+1 Rare | 2 | Phase 2 | $10.4B | 5 |
| KYTX | Kyverna Therapeutics | ImmunologyNeurology+1 Rare | 2 | NDA Submitted | $297M | 6 |
| LBRX | LB Pharmaceuticals | Neurology | 1 | Phase 3 | $1.30B | 3 |
| LXEO | Lexeo Therapeutics | CardiovascularNeurology Rare | 1 | Phase 2 | $236M | 12 |
| LCTX | Lineage Cell Therapeutics | MetabolicNeurology+1 Rare | 1 | Phase 2 | $207M | 13 |
| LGVN | Longeveron | CardiovascularNeurology Rare | 2 | Phase 2 | $7.1M | 3 |
| MPLT | MapLight Therapeutics | Neurology | 3 | Phase 2 | $365M | 3 |
| MAZE | Maze Therapeutics | MetabolicRenal Rare | 3 | Phase 2 | $1.80B | 4 |
| MDNAF | Medicenna Therapeutics | Oncology | 1 | Phase 2 | $14.8M | 10 |
| MGTX | MeiraGTx | ImmunologyMetabolic+2 Rare | 2 | Phase 3 | $827M | 16 |
| MLYS | Mineralys Therapeutics | CardiovascularRenal+1 | 2 | NDA Submitted | $1.28B | 3 |
| INKT | MiNK Therapeutics | ImmunologyOncology+1 Rare | 3 | Phase 2 | $47.7M | 8 |
| MBRX | Moleculin Biotech | Oncology | 3 | Phase 2 | $7.3M | 9 |
| GLUE | Monte Rosa Therapeutics | CardiovascularDermatology+3 Rare | 2 | Phase 2 | $775M | 7 |
| MLTX | MoonLake Immunotherapeutics | DermatologyImmunology Rare | 2 | NDA Submitted | $957M | 4 |
| NKTR | Nektar Therapeutics | DermatologyImmunology+2 | 5 | Phase 3 | $1.23B | 11 |
| NRSN | NeuroSense Therapeutics | Neurology Rare | 2 | Phase 2 | $2.9M | 3 |
| NAMS | NewAmsterdam Pharma | CardiovascularMetabolic+1 | 1 | NDA Submitted | $2.33B | 6 |
| NBP | NovaBridge Biosciences | OncologyOphthalmology | 3 | Phase 2 | $95.4M | 7 |
| NRXP | NRX Pharmaceuticals | Neurology Rare | 1 | Approved | $109M | 11 |
| NRIX | Nurix Therapeutics | ImmunologyNeurology+1 | 2 | Phase 3 | $1.56B | 13 |
| NVCT | Nuvectis Pharma | HematologyOncology+1 Rare | 1 | Phase 3 | $660M | 9 |
| OCGN | Ocugen | Infectious DiseaseOphthalmology Rare | 1 | Phase 3 | $257M | 12 |
| OCS | Oculis Holding | NeurologyOphthalmology Rare | 1 | Phase 3 | $418M | 5 |
| OMER | Omeros | HematologyNeurology+2 Rare | 1 | Approved | $1.04B | 6 |
| ONCY | Oncolytics Biotech | Oncology | 2 | Phase 2 | $51.7M | 4 |
| IRD | Opus Genetics | Ophthalmology Rare | 1 | Approved | $391M | 12 |
| ORKA | Oruka Therapeutics | DermatologyImmunology Rare | 3 | Phase 2 | $6.53B | 7 |
| OVID | Ovid Therapeutics | Neurology Rare | 1 | Phase 2 | $419M | 4 |
| PTN | Palatin Technologies | ImmunologyMetabolic+1 | 2 | Phase 3 | $9.5M | 5 |
| PALI | Palisade Bio | Immunology | 1 | Phase 2 | $181M | 3 |
| PEPG | PepGen | Neurology Rare | 1 | Phase 2 | $269M | 1 |
| PMVP | PMV Pharmaceuticals | Oncology | 7 | Phase 2 | $92.2M | 7 |
| PCSA | Processa Pharmaceuticals | GI/HepatologyImmunology+2 Rare | 1 | Phase 2 | $4.8M | 7 |
| PTGX | Protagonist Therapeutics | DermatologyHematology+2 Rare | 1 | Approved | $8.14B | 12 |
| TARA | Protara Therapeutics | DermatologyMetabolic+1 Rare | 2 | Phase 3 | $143M | 3 |
| QTTB | Q32 Bio | Dermatology | 1 | Phase 2 | $258M | 3 |
| QNRX | Quoin Pharmaceuticals | DermatologyImmunology Rare | 2 | Phase 2 | $236M | 4 |
| RAPP | Rapport Therapeutics | Neurology | 1 | Phase 3 | $1.41B | 6 |
| RXRX | Recursion Pharmaceuticals | Oncology | 1 | Phase 2 | $1.69B | 6 |
| RNTX | Rein Therapeutics | Respiratory Rare | 1 | Phase 2 | $30.7M | 1 |
| RLAY | Relay Therapeutics | DermatologyOncology Rare | 1 | Approved | $3.64B | 4 |
| RLMD | Relmada Therapeutics | MetabolicNeurology+1 Rare | 3 | Phase 2 | $321M | 4 |
| REPL | Replimune Group | Oncology | 4 | Approved | $1.87B | 5 |
| RYTM | Rhythm Pharmaceuticals | Metabolic Rare | 2 | Approved | $8.08B | 14 |
| RCKT | Rocket Pharmaceuticals | CardiovascularImmunology Rare | 1 | Approved | $236M | 4 |
| SABS | SAB Biotherapeutics | Metabolic | 1 | Phase 2 | $266M | 1 |
| SGMT | Sagimet Biosciences | DermatologyMetabolic | 1 | Phase 3 | $709M | 3 |
| SLS | SELLAS Life Sciences Group | Oncology | 1 | Phase 3 | $3.90B | 9 |
| SION | Sionna Therapeutics | Respiratory Rare | 1 | Phase 2 | $139M | 5 |
| SYRE | Spyre Therapeutics | DermatologyImmunology Rare | 9 | Phase 2 | $8.91B | 10 |
| SMMT | Summit Therapeutics | Oncology | 2 | NDA Submitted | $8.53B | 6 |
| TECX | Tectonic Therapeutic | Cardiovascular Rare | 2 | Phase 2 | $401M | 4 |
| TLX | Telix Pharmaceuticals | Oncology | 3 | Approved | $3.01B | 25 |
| TGTX | Tg Therapeutics | Neurology Rare | 2 | Approved | $9.48B | 6 |
| TLSA | Tiziana Life Sciences | ImmunologyNeurology Rare | 4 | Phase 2 | $83.2M | 5 |
| TVTX | Travere Therapeutics | MetabolicRenal Rare | 1 | Approved | $4.91B | 7 |
| TTRX | Turn Therapeutics | DermatologyInfectious Disease Rare | 1 | Phase 2 | $261M | 4 |
| TYRA | Tyra Biosciences | MetabolicOncology Rare | 3 | Phase 2 | $1.35B | 5 |
| UPB | Upstream Bio | Respiratory | 3 | Phase 2 | $115M | 3 |
| VNDA | Vanda Pharmaceuticals | CardiovascularDermatology+6 Rare | 2 | Approved | $230M | 27 |
| PCVX | Vaxcyte | Infectious Disease | 1 | Phase 3 | $9.40B | 7 |
| VERA | Vera Therapeutics | Infectious DiseaseRenal Rare | 4 | Approved | $1.89B | 6 |
| VSTM | Verastem | Oncology | 4 | Approved | $934M | 5 |
| VRCA | Verrica Pharmaceuticals | DermatologyOncology Rare | 1 | Approved | $53.9M | 4 |
| VKTX | Viking Therapeutics | MetabolicNeurology Rare | 4 | Phase 3 | $3.43B | 9 |
| VTVT | vTv Therapeutics | HematologyMetabolic+1 Rare | 3 | Phase 3 | $69.4M | 9 |
| WVE | Wave Life Sciences | MetabolicNeurology+1 Rare | 1 | Phase 2 | $560M | 5 |
| XNCR | Xencor | ImmunologyNeurology+1 Rare | 3 | Approved | $2.59B | 28 |
| XERS | Xeris Biopharma | MetabolicNeurology Rare | 1 | Approved | $3.07B | 4 |
| ZBIO | Zenas BioPharma | DermatologyImmunology+2 Rare | 2 | NDA Submitted | $1.88B | 11 |
| ZURA | Zura Bio | DermatologyImmunology Rare | 2 | Phase 2 | $99.7M | 4 |
No companies match.